Utility of health states in chronic kidney disease: a structured review of the literature

References

• Johnson CA, Levey AS, Coresh J, et al. Clinical practice guidelines for chronic kidney disease in adults: part I. Definition, disease stages, evaluation, treatment, and risk factors. Am Fam Physician 2004;70:869–76
   PubMed Web of Science ®Google Scholar
• Meguid El, Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005;365:331–40
   PubMed Web of Science ®Google Scholar
• Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States renal data system 2006 annual data report. Am J Kidney Dis 2007;49(Suppl 1):A6–7, S1–S296
   Google Scholar
• Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1–12
   PubMed Web of Science ®Google Scholar
• Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005;20:2587–93
   PubMed Web of Science ®Google Scholar
• Bakewell AB, Higgins RM, Edmunds ME. Quality of life in peritoneal dialysis patients: decline over time and association with clinical outcomes. Kidney Int 2002;61:239–48
   Google Scholar
• Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 2005;68:2801–8
   PubMed Web of Science ®Google Scholar
• Mingardi G. From the development to the clinical application of a questionnaire on the quality of life in dialysis. The experience of the Italian Collaborative DIA-QOL (Dialysis-Quality of Life) Group. Nephrol Dial Transplant 1998;13(Suppl 1):70–5
   PubMedGoogle Scholar
• Gudex CM. Health-related quality of life in end stage renal failure. Qual Life Res 1995;4:359–66
   PubMed Web of Science ®Google Scholar
• de Wit GA, Merkus MP, Krediet RT, de Charro FT. Health profiles and health preferences of dialysis patients. Nephrol Dial Transplant 2002;17:86–92
   PubMedGoogle Scholar
• Hays RD, Kellich JD, Mapse DL, et al. Kidney disease and quality of life short form (KDQOL-SF™), version 1.1: a manual for use and scoring. Santa Monica: RAND; 1995. p. 7928
   Google Scholar
• Razvi S, McMillan CV, Weaver JU. Instruments used in measuring symptoms, health status and quality of life in hypothyroidism: a systematic qualitative review. Clin Endocrinol 2005;63:617–24
   Google Scholar
• Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83
   Google Scholar
• Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981;19:787–805
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118:622–9
   Google Scholar
• Gold MR, Siegel JE, Russell LB. Cost effectiveness in health and medicine. New York (NY): Oxford University press; 1996
   Google Scholar
• Anon. Guide to the methods of technology appraisal (reference N0515) 7 May 2004. National Institute for Health and Clinical Excellence (NICE),London, UK. Available at www.nice.org.uk/page.aspx?o=201973 [last accessed 1 June 2007]
   Google Scholar
• Brooks R, EuroQol Group. EuroQol: the current state of play. Health Policy 1996;37:53–72
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–108
   PubMed Web of Science ®Google Scholar
• Feeny DH, Furlong WJ, Torrance GW, et al. Multi-attribute and single-attribute utility function: the Health Utility Index Mark 3 system. Med Care 2002;40:113–28
   PubMed Web of Science ®Google Scholar
• Brazier J, Roberts J, Deverill M. The estimation of a preference-based single index measure for health from the SF-36. J Health Economics 2002;21: 271–92
   Google Scholar
• Kaplan RM, Bush JW, Berry CC. Health status index: category rating versus magnitude estimation for measuring levels of wellbeing. Med Care 1979;17:501–25
   Google Scholar
• Sennfalt K, Magnusson M, Carlsson P. Comparison of haemodialysis and peritoneal dialysis – a cost-utility analysis. Peritoneal Dial Int 2002;22:39–47
   PubMed Web of Science ®Google Scholar
• Manns B, Johnson JA, Taub K, et al. Quality of life in patients treated with haemodialysis or peritoneal dialysis: what are the important determinants? Clin Nephrol 2003;60:341–51
   PubMed Web of Science ®Google Scholar
• Bass EB, Wills S, Fink NE, et al. How strong are patients’ preferences in choices between dialysis modalities and doses? Am J Kidney Dis 2004;44:695–705
   PubMed Web of Science ®Google Scholar
• Groome PA, Hutchinson TA, Tousignant P, Hanley JA. The repeatability of three methods for measuring prospective patients’ values in the context of treatment choice for end-stage renal disease. J Clin Epidemiol 1999;52:849–60
   PubMed Web of Science ®Google Scholar
• Arredondo A, Rangel R, de Icaza E. Cost-effectiveness of interventions for end-stage renal disease. Revista de Saude Publica 1998;32:556–65
   PubMedGoogle Scholar
• de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998;44:215–32
   Google Scholar
• Molzahn AE, Northcott HC, Hayduk L. Quality of life of patients with end stage renal disease: a structural equation model. Qual Life Res 1996;5:426–32
   Google Scholar
• Churchill DN, Torrance GW, Taylor DW, et al. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med 1987;10:14–20
   PubMed Web of Science ®Google Scholar
• Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990;300:573–8
   PubMed Web of Science ®Google Scholar
• Revicki DA. Relationship between health utility and psychometric health status measures. Med Care 1992;30 (Suppl 5):MS274–MS282
   Google Scholar
• Leese B, Hutton J, Maynard A. A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries. Pharmacoeconomics 1992;1: 346–56
   Google Scholar
• Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. Br Med J 1995;311:1595–9
   PubMed Web of Science ®Google Scholar
• Douzdjian V, Ferrara D, Silvestri G. Treatment strategies for insulin-dependent diabetics with ESRD: a cost-effectiveness decision analysis model. Am J Kidney Dis 1998;31:794–802
   Google Scholar
• Postulart D, Adang EM. Response shift and adaptation in chronically ill patients. Med Decis Making 2000;20:186–93
   PubMed Web of Science ®Google Scholar
• Holohan TV. Cost-effectiveness modeling of simultaneous pancreas–kidney transplantation. Int J Technol Assess Health Care 1996;12:416–24
   PubMed Web of Science ®Google Scholar
• Russell JD, Beecroft ML, Ludwin D, Churchill DN. The quality of life in renal transplantation – a prospective study. Transplantation 1992;54:656–60
   PubMed Web of Science ®Google Scholar
• Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996;50:235–42
   PubMed Web of Science ®Google Scholar
• Greiner W, Obermann K, Schulenburg JM. Socio-economic evaluation of kidney transplantation in Germany. Arch Hell Med 2001;18:147–55
   Google Scholar
• de Wit GA, Merkus MP, Krediet RT, de Charro FT. A comparison of quality of life of patients on automated and continuous ambulatory peritoneal dialysis. Peritoneal Dial Int 2001;21:306–12
   PubMedGoogle Scholar
• Kontodimopoulos N, Niakas D. Overcoming inherent problems of preference-based techniques for measuring health benefits: an empirical study in the context of kidney transplantation. BMC Health Serv Res 2006;6:3
   PubMed Web of Science ®Google Scholar
• Molzahn AE, Northcott HC, Dossetor JB. Quality of life of individuals with end stage renal disease: perceptions of patients, nurses, and physicians. ANNA J 1997;24:325–33 [discussion 334–5]
   Google Scholar
• Lawrence WF, Grist TM, Brazy PC. Magnetic resonance angiography in progressive renal failure: a technology assessment. Am J Kidney Dis 1995;25:701–9
   Google Scholar
• Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensinconverting enzyme inhibitors. Ann Intern Med 1999;131: 660–7
   Google Scholar
• Heidenheim AP, Muirhead N, Moist L, Lindsay RM. Patient quality of life on quotidian haemodialysis. Am J Kidney Dis 2003;42(Suppl 1):36–41
   PubMedGoogle Scholar
• Rasanen P, Roine E, Sintonen H, et al. Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. Int J Technol Assess Health Care 2006;22:235–41
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Greenberg D, Olchanski NV, et al. Growth and quality of the cost-utility literature, 1976–2001. Value Health 2005;8:3–9
   PubMed Web of Science ®Google Scholar
• Veenhoven R. Happy life-expectancy. A comprehensive measure of quality-of-life in nations. Soc Indicators Res 1996;39:1–58
   Web of Science ®Google Scholar
• Tengs TO, Yu M, Luistro E. Health-related quality of life after stroke: a comprehensive review. Stroke 2001;32:964–72
   Google Scholar
• Arnesen T, Trommald M. Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method. J Health Serv Res Policy 2004;9:43–50
   PubMedGoogle Scholar
• Lenert LA, Treadwell JR, Schwartz CE. Associations between health status measures and utilities: implications for policy. Medical Care 1999;37:479–89
   Google Scholar
• Churchill DN, Wallace JE, Ludwin D, et al. A comparison of evaluative indices of quality of life and cognitive function in haemodialysis patients. Control Clin Trials 1991;12 (Suppl 4):159S–167S
   Google Scholar
• Churchill DN, Bird DR, Taylor DW, et al. Effect of high-flux haemodialysis on quality of life and neuropsychological function in chronic haemodialysis patients. Am J Nephrol 1992;12:412–8
   PubMed Web of Science ®Google Scholar
• Hamel MB, Phillips RS, Davis RB, et al. Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults [SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments]. Ann Intern Med 1997;127:195–202
   Google Scholar
• Hornberger JC, Redelmeier DA, Petersen J. Variability among methods to assess patients‘ well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol 1992;45:505–12
   Google Scholar
• Lenert LA, Hornberger JC. Computer-assisted quality of life assessment for clinical trials. Proc AMIA Annu Fall Symp 1996;1:992–6
   Google Scholar
• Maor Y, King M, Olmer L, Mozes B. A comparison of three measures: the time trade-off technique, global health-related quality of life and the SF-36 in dialysis patients. J Clin Epidemiol 2001;54:565–70
   PubMed Web of Science ®Google Scholar
• McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA. The quality of life and cost utility of home nocturnal and conventional in-centre haemodialysis. Kidney Int 2003;64:1004–11
   PubMed Web of Science ®Google Scholar
• Sesso R, Yoshihiro MM. Time of diagnosis of chronic renal failure and assessment of quality of life in haemodialysis patients. Nephrol Dial Transplant 1997;12:2111–6
   PubMed Web of Science ®Google Scholar